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Narcolepsy with cataplexy is a rare, but important differential diagnosis for daytime 
sleepiness and atonic paroxysms in an adolescent. A recent increase in incidence in 
the pediatric age group probably linked to the use of the Pandemrix influenza vaccine 
in 2009, has increased awareness that different environmental factors can “trigger” 
narcolepsy with cataplexy in a genetically susceptible population. Here, we describe the 
case of a 13-year-old boy with narcolepsy following yellow fever vaccination. He carries 
the HLA DQB1*0602 haplotype strongly associated with narcolepsy and cataplexy. 
Polysomnography showed rapid sleep onset with rapid eye movement (REM) latency 
of 47 min, significant sleep fragmentation and a mean sleep latency of 1.6 min with 
sleep onset REM in four out of four nap periods. Together with the clinical history, these 
findings are diagnostic of narcolepsy type 1. The envelope protein E of the yellow fever 
vaccine strain 17D has significant amino acid sequence overlap with both hypocretin 
and the hypocretin receptor 2 receptors in protein regions that are predicted to act as 
epitopes for antibody production. These findings raise the question whether the yellow 
fever vaccine strain may, through a potential molecular mimicry mechanism, be another 
infectious trigger for this neuro-immunological disorder.
Keywords: sleep disorders, molecular immunogene, HLa, pediatric neurology
INtRoDUCtIoN
Narcolepsy is a rare, lifelong sleep disorder that is usually diagnosed in adolescence and early 
adulthood. It is classified as narcolepsy type 1 vs. narcolepsy type 2 according to the presence 
or absence of cataplexy and cerebrospinal fluid (CSF) hypocretin deficiency (1). While the exact 
etiology is unclear, narcolepsy with cataplexy is strongly associated with a significant loss of hypo-
cretin-secreting neurons in the lateral hypothalamus alongside reduced CSF hypocretin-1 levels. 
Furthermore, there is a well-documented association with HLA DQB1*0602, suggesting a possible 
autoimmune etiology (2). Here, we present a patient from our tertiary pediatric clinical service, 
who has a clear history of narcolepsy with cataplexy following recent yellow fever vaccination.
A recent increase in reported cases of narcolepsy with cataplexy has been associated both with 
the use of the ASO3-conjugated split-virion H1N1 vaccine Pandemrix in 2009 (3), and with H1N1 
infection (4). Influenza nucleoprotein antibodies have been shown to cross-react with hypocretin 
receptors (HCRTR1, HCRTR2), suggesting a form of molecular mimicry as the cause for the hypo-
cretin neuron loss (5). Most patients with this “post-vaccination” narcolepsy develop symptoms at 
taBLe 1 | polysomnography results of the patient at time of diagnosis.
Measurement Value Reference
Nocturnal polysomnography
Total sleep time, min 646.6 –
Sleep onset latency, min 0.7 (rapid) 23 (SD = 25)
REM latency, min 47 (rapid) 88 (SD = 41)
Arousal index, per hour 16.4 (slightly elevated) 9.3 (SD = 4.8)
Sleep efficiency 82.5% (slightly low) 89 (SD = 7.5)
Oxygen saturation, % 98.1 >96
Apnea hypopnea index, per hour 1.5 1 (SD = 0.8)
sleep stages, % of total sleep time
N1 5.9 ~6b
N2 41.1 ~49b
N3 18.5 ~23b
REM 34.5 ~22b
Multiple sleep latency test
Mean sleep latency test, min 1.6 (rapid) >8a
Sleep onset REM periods 4 of 4 nap periods  
(suggestive of narcolepsy)
0a
aIndicates significantly abnormal results.
bReference values from Ref. (6) given for comparison, no confidence intervals given.
REM, rapid eye movement.
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a younger than usual age with abrupt onset of cataplexy shortly 
after the vaccination (mean interval 7  weeks), resulting in an 
increase of narcolepsy incidence in the pediatric age group in 
recent years.
Case RepoRt
A 13-year-old boy attended pediatric neurology clinic with a 
2-year history of repeated paroxysmal muscle tone loss, in order 
to be assessed for possible atonic seizures. Having been previ-
ously neurologically intact, symptoms started with an episode 
in a restaurant where he abruptly lost axial tone and his head 
hit the table. He subsequently experienced frequent similar 
episodes, especially when experiencing positive emotions, dur-
ing laughter or while playing games with excitement. Episodes 
were varied as follows: they ranged from subtle involuntary head 
nods, which he could conceal and were not always noticed by 
others, to complete postural collapse. They were consistently 
symmetrical, involving both the left and right side of his body. 
All instances were described as short-lived, lasting no longer 
than a few seconds.
During the same period, he would drift off to sleep several 
times a day without warning, and not wake up until roused. 
At night, his sleep was interrupted, waking up frightened while 
feeling unable to move. In addition, his mother also noticed a 
marked weight gain associated with a significant increase in his 
appetite. He was previously well, with an unremarkable birth and 
family history. He never received the Pandemrix influenza vac-
cine, but ~2 weeks prior to symptom onset had been vaccinated 
with the Stamaril live, attenuated yellow fever vaccine for a family 
trip to Africa.
Neurological clinical examination was unremarkable and 
initial investigations, including electrocardiography (ECG), brain 
magnetic resonance imaging (MRI), and routine blood tests were 
within normal limits. Polysomnography (PSG) showed rapid sleep 
onset with rapid eye movement (REM) latency of 47 min (normal 
70–110, full results given in Table  1, hypnogram of overnight 
sleep and multiple sleep latency is shown in Figure 1). He had 
significant sleep fragmentation, with frequent REM intrusions 
interrupting the usual consolidation of non-REM periods but no 
evidence of sleep disordered breathing. Multiple sleep latency test 
(MSLT) performed the following day was significantly abnormal 
with a mean sleep latency of 1.6 min (normal >8 min) and sleep 
onset REM evident in four out of four nap periods.
The clinical history of weight gain, hypnagogic hallucinations, 
sleep paralysis, and clear episodes of loss of muscle tone (cataplexy) 
is strongly suggestive of narcolepsy. With that clinical context, 
the fragmented sleep without sleep disordered breathing on PSG 
together with significantly shortened sleep latency and sleep onset 
REM on MSLT confirmed the diagnosis of narcolepsy. Periods of 
non-REM sleep were interrupted by REM intrusions, resulting 
in a proportional increase in REM sleep compared to non-REM 
sleep phases (as indicated in Table 1). While sleep fragmentation 
does occur for other reasons, this pattern shown on PSG is typi-
cal of young patients with untreated narcolepsy. These findings 
taken together meet level 2 evidence for narcolepsy according to 
the criteria laid out by the Brighton Collaboration Narcolepsy 
Working Group (7), as well as fulfilling the diagnostic criteria for 
narcolepsy type 1 defined in the International Classification of 
Sleep Disorders, third edition (1).
He was found to have the strongly associated HLA-type 
DQB1*0602. MRI brain, including T1 and T2 weighted scan and 
FLAIR imaging was normal, with normal hypothalamic appear-
ances. Because of the clear clinical history of cataplexy and the 
invasiveness of the procedure in a pediatric patient, CSF levels of 
hypocretin (orexin) were not measured. Treatment was mainly 
directed at managing daytime sleepiness through improved sleep 
hygiene and daytime naps, in addition to stimulant medication 
(slow release methylphenidate, 18  mg once a day increased in 
two steps to 45 mg once a day) and anti-cataplectic medication 
(venlafaxine, 37.5 mg once a day).
DIsCUssIoN
The case presented here raises the possibility that currently 
unknown combinations of genetic susceptibilities and environ-
mental triggers may play a role in the etiology of narcolepsy in 
some patients. Our patient never received Pandemrix, while 
having received the yellow fever vaccine Stamaril 2  weeks 
prior to cataplexy onset. In cases reported in association 
with Pandemrix, the risk of developing narcolepsy was most 
increased in this early post-vaccination time period (8–42 days) 
(8). The yellow fever vaccines induce a strong immune response, 
and the YFV-17D strain used in the Stamaril vaccines contains 
multiple antigens with several epitopes each that can bind differ-
ent HLA molecules (9). While yellow-fever-vaccine-associated 
neurological disease is described, narcolepsy is not currently a 
recognized complication (10).
Previous studies have shown that the association with HLA 
DQB1*0602 is extremely high in patients with typical or severe 
cataplexy [85–95% of patients show this HLA type vs. 25% of 
age-matched controls (11)]. Together with epidemiological 
FIGURe 1 | (a) Hypnogram of nocturnal polysomnography for patient showing significant sleep fragmentation with frequent arousals and awakenings, particularly 
during N2 sleep. The image also shows the short sleep latency and frequent sleep onset REM episodes after awakenings. (B) Hypnogram of multiple sleep latency 
showing sleep onset REM in 4 of 4 nap periods.
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associations between narcolepsy onset and different environ-
mental triggers [including Streptococcus sp. Infection (12), H1N1 
infection (13), and the Pandemrix vaccine (7)], an immune-
mediated, environmentally triggered etiology appears most likely 
(14). Most recently, different lines of evidence have suggested that 
the H1N1- and Pandemrix-associated cases of narcolepsy are 
caused by molecular mimicry between influenza epitopes and 
hypocretin receptor domains with associated antibody-mediated 
destruction of hypocretin-secreting neurons (5).
The attenuated yellow fever strain used in the Stamaril vaccine 
(YFV-17D) carries a genome that codes for 13 distinct proteins 
and peptides [UniProt ID P03314 (15)]. Amino acid sequences 
for each of the 17D strain peptides and proteins were assessed 
for sequence overlap with hypocretin, HCRTR1, and HCRTR2 
using the BLAST algorithm (see blast.ncbi.nlm.nih.gov for more 
information). Of these, four show significant amino acid sequence 
similarities to hypocretin or one of its receptors (Table 2).
Sequence overlaps in extracellular domains of the human 
proteins are of particular interest as these are the most plausible 
target for putative antibody-mediated molecular mimicry. Only 
one of the viral peptides (the envelope protein E) has sequence 
overlaps with extracellular protein components (i.e., hypocretin, 
or external domains of the hypocretin receptors).
Sections within the same protein sequence are also predicted 
to act as epitopes for B-cell linear proliferation (Figure 2). These 
findings taken together illustrate one specific possible mechanism 
for molecular mimicry between the yellow fever vaccine strain, 
and hypocretin-secreting neurons: antibodies are produced to 
epitopes found in the envelope protein E sequence as part of 
the strong immune response to the vaccine. These may then 
cross-react with either hypocretin molecules themselves, or an 
extracellular domain of the hypocretin receptor 2, because of the 
amino acid sequence similarities between the vaccine epitopes 
and the hypocretin or receptor molecules.
Clearly, our single case does not allow any inference whether 
Stamaril has causally contributed to the development of nar-
colepsy in this patient. Hypocretin-associated autoantibodies, 
where detected at all, do not seem to be more common in patients 
with narcolepsy compared to controls (18, 19). And even for the 
Pandemrix vaccine, where there is strong epidemiological evidence 
for a causative link, there is conflicting evidence as to whether 
molecular mimicry plays a role in the pathophysiology (5, 20).
Yet our case raises the consideration as to whether other 
associations between environmental triggers and narcolepsy 
onset exist, particularly in the context of the genetic susceptibility 
conferred by the associated HLA type.
FIGURe 2 | amino acid sequence overlap between a segment of the YFV-17D envelope protein e (epe), the human hypocretin receptor 2 (HR2, top), 
and hypocretin (HCt, bottom). Blue letters in the EPE sequence show amino acids that are predicted to constitute an epitope for B-cells [BepiPred Linear Epitope 
Prediction, see tools.immuneepitope.org (16)]. Amino acids are grouped into six groups according to a composite difference score calculated from polarity, volume, 
and composition. They are classified as similar where they belong to the same group (17).
taBLe 2 | sequence overlap between YFV-D17 proteins and hypocretin and its receptors.
protein/peptide aa# Reference sequence aa# Cellular location E-value
Capsid protein C 2–13 Hypocretin receptor 1 157–168 Cytoplasmic/transmemrbrane 0.14
Capsid protein C 65–74 Hypocretin receptor 2 262–271 Cytoplasmic 0.29
Envelope protein E 224–235 Hypocretin receptor 2 43–54 Extracellular 0.47
Envelope protein E 218–253 Hypocretin 70–103 Extracellular 0.055
Non-structural protein 2A-alpha 128–152 Hypocretin receptor 2 137–161 Cytoplasmic/transmembrane 0.63
Serine protease subunit NS2B 95–108 Hypocretin receptor 2 422–435 Cytoplasmic 0.11
AA#, position in the amino acid sequence (start–stop); E-value, “Expect” value is a parameter that describes the number of hits “expected” chance results; the lower the score, the 
more “significant” the match is (see http://blast.ncbi.nlm.nih.gov/ for more information).
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CoNCLUsIoN
Narcolepsy with cataplexy in children is strongly associated 
with HLA DQB1*0602 and a loss of hypothalamic hypocretin-
secreting neurons. There is epidemiological evidence that a recent 
increase in narcolepsy diagnoses in children was linked to the 
H1N1 mass vaccination.
The close temporal association of the live-attenuated yellow 
fever vaccine, associated with genetic susceptibility, and the 
potential for molecular mimicry between MHC-derived peptides, 
hypocretin, its receptors, and the viral envelope protein E raises 
the question as to whether the vaccine was involved in the pathol-
ogy here. Exploring any such association will need further careful 
evaluation using epidemiological approaches. The next step for 
this will be a detailed evaluation of the incidence of narcolepsy in 
possible at risk population (i.e., patients exposed to yellow fever in 
endemic regions, young people undergoing yellow fever vaccine). 
As with the Pandemrix vaccine-related cases, further longitudinal 
follow-up is necessary, as it is not yet clear whether presumed 
vaccine-associated cases follow the same natural history as seen 
in other narcolepsy patients.
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